NASDAQ:ENTA - Enanta Pharmaceuticals Stock Price, Forecast & News

Enanta Pharmaceuticals' stock was trading at $52.92 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ENTA shares have decreased by 4.9% and is now trading at $50.34. View which stocks have been mosted impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last year. There are currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Enanta Pharmaceuticals.

Enanta Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Enanta Pharmaceuticals.

Enanta Pharmaceuticals Inc (NASDAQ:ENTA) posted its quarterly earnings data on Thursday, February, 6th. The biotechnology company reported $0.65 earnings per share for the quarter, topping the consensus estimate of $0.59 by $0.06. The biotechnology company earned $52.57 million during the quarter, compared to analyst estimates of $58.75 million. Enanta Pharmaceuticals had a return on equity of 7.39% and a net margin of 18.00%. The company's revenue was down 24.8% on a year-over-year basis. During the same period in the previous year, the company earned $1.25 earnings per share. View Enanta Pharmaceuticals' earnings history.

5 Wall Street analysts have issued 1-year price targets for Enanta Pharmaceuticals' shares. Their forecasts range from $57.00 to $130.00. On average, they expect Enanta Pharmaceuticals' share price to reach $91.00 in the next twelve months. This suggests a possible upside of 80.8% from the stock's current price. View analysts' price targets for Enanta Pharmaceuticals.

News coverage about ENTA stock has been trending very negative on Thursday, InfoTrie reports. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Enanta Pharmaceuticals earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutEnanta Pharmaceuticals.

Enanta Pharmaceuticals saw a drop in short interest in February. As of February 28th, there was short interest totaling 1,940,000 shares, a drop of 8.5% from the February 13th total of 2,120,000 shares. Based on an average daily trading volume, of 214,100 shares, the short-interest ratio is currently 9.1 days. Approximately 11.0% of the shares of the stock are sold short. View Enanta Pharmaceuticals' Current Options Chain.

Some companies that are related to Enanta Pharmaceuticals include BridgeBio Pharma (BBIO), Evotec (EVTCY), Mirati Therapeutics (MRTX), Nektar Therapeutics (NKTR), Blueprint Medicines (BPMC), Global Blood Therapeutics (GBT), Zai Lab (ZLAB), FibroGen (FGEN), Emergent Biosolutions (EBS), Arrowhead Pharmaceuticals (ARWR), PTC Therapeutics (PTCT), PPD (SDGR), GW Pharmaceuticals PLC- (GWPH), Ultragenyx Pharmaceutical (RARE) and ChemoCentryx (CCXI).

Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include Verizon Communications (VZ), HCA Healthcare (HCA), Pandora Media (P), Ryder System (R), Tandem Diabetes Care (TNDM), Wells Fargo & Co (WFC), NVIDIA (NVDA), Ford Motor (F), Alibaba Group (BABA) and Tesla (TSLA).

Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."

Shares of ENTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ENTA stock can currently be purchased for approximately $50.34.

Enanta Pharmaceuticals has a market capitalization of $1.00 billion and generates $205.20 million in revenue each year. The biotechnology company earns $46.38 million in net income (profit) each year or $2.21 on an earnings per share basis. Enanta Pharmaceuticals employs 113 workers across the globe. View additional information about Enanta Pharmaceuticals.

The official website for Enanta Pharmaceuticals is http://www.enanta.com/.

Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The biotechnology company can be reached via phone at 617-607-0800 or via email at [email protected]